Valuation: StemCell Institute Inc.

Market Cap 7.87B 48.59M 42.46M 39.25M 36.27M 68.3M 4.67B 69.53M 468M 184M 2.29B 183M 178M P/E 2026
49.6x
P/E 2027 * 70.5x
Enterprise Value 7.87B 48.59M 42.46M 39.25M 36.27M 68.3M 4.67B 69.53M 468M 184M 2.29B 183M 178M EV / Sales 2026
2.79x
EV / Sales 2027 * 2.54x
Free-Float
23.41%
Yield 2026 *
-
Yield 2027 * -
1 day+0.39%
1 week+1.32%
Current month+6.08%
1 month+14.80%
3 months-0.13%
6 months-11.32%
Current year-3.15%
1 week 750
Extreme 750
775
1 month 651
Extreme 651
775
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,245
3 years 627
Extreme 627
3,225
5 years 627
Extreme 627
3,610
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 31/05/2016
Director TitleAgeSince
Director/Board Member 66 31/05/2020
Director/Board Member 53 31/08/2013
Director/Board Member 81 31/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%+1.32%-30.56%-74.94% 48.4M
+0.31%+1.65%+66.08%+49.21% 135B
+2.59%-9.13%+0.35%+27.84% 80.66B
+1.77%-1.63%+0.72%+59.69% 26.44B
-0.67%-1.71%+22.97%+46.27% 22.8B
-0.84%-2.25%-18.43%-28.92% 19.96B
+3.94%-7.91%+9.93%+135.52% 15.82B
+0.80%+6.87%+8.17%+11.04% 15.63B
-1.56%-1.01%+62.52%+118.49% 14.92B
-1.12%-0.07%-9.39%-11.85% 12.9B
Average +0.57%-3.04%+11.24%+33.23% 34.47B
Weighted average by Cap. +0.90%-3.70%+29.74%+43.22%

Financials

2026 2027 *
Net sales 2.87B 17.72M 15.49M 14.32M 13.23M 24.91M 1.7B 25.36M 171M 66.99M 834M 66.57M 65.09M 3.1B 19.14M 16.73M 15.46M 14.29M 26.9M 1.84B 27.39M 184M 72.35M 900M 71.9M 70.31M
Net income 180M 1.11M 971K 898K 830K 1.56M 107M 1.59M 10.71M 4.2M 52.28M 4.17M 4.08M 110M 679K 594K 549K 507K 955K 65.24M 972K 6.54M 2.57M 31.95M 2.55M 2.49M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
15/07/26 JP¥768.00 +0.39% 1,900
14/07/26 JP¥765.00 -0.65% 4,300
13/07/26 JP¥770.00 +0.26% 2,400
10/07/26 JP¥768.00 +0.92% 3,000
09/07/26 JP¥761.00 +0.40% 13,800

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock